Methylhomatropine

Summary

Methylhomatropine (CHEMBL1201235) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 290.4 Da · C17H24NO3+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201235
Name	Methylhomatropine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5282592
Molecular formula	C17H24NO3+
Molecular weight	290.4
InChIKey	WKWOJBUWWZTUQV-PJPHBNEVSA-N

SMILES: C[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)O)C

IUPAC name: [(1R,5S)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2-phenylacetate

Also known as: Methylhomatropine cation, Methylhomatropine ion, methylhomatropine

Parent form; salt/anhydrous children: CHEMBL1200851

Patent coverage: 1 distinct patent families (1 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CHRM2	6.86	AC50	138.7	nM	CHEMBL_ACT_25196139
CHRM1	6.66	AC50	220	nM	CHEMBL_ACT_25210554

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).